Privium Fund Management’s Beam Therapeutics BEAM Stock Holding History

Privium Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41M	Buy	70,282 +6,300	+10%	+$190K	0.44%	35
2026 Q1	$1.52M	Sell	63,982 -7,518	-11%	-$209K	0.32%	38
2025 Q4	$1.98M	Buy	71,500 +10,500	+17%	+$268K	0.36%	32
2025 Q3	$1.48M	Buy	+61,000	New	+$1.21M	0.27%	35

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Privium Fund Management's BEAM Position: Q2 2026 in Review

Privium Fund Management increased its Beam Therapeutics (BEAM) stake by 9.8% in Q2 2026, buying an estimated $190K and bringing the position to 70,282 shares worth $2.41M. The position accounts for 0.44% of the portfolio, ranked #35.

Privium Fund Management first reported a position in BEAM in Q3 2025 and has held it in 4 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Privium Fund Management held 70,282 shares of Beam Therapeutics worth $2.41M as of Q2 2026.
Privium Fund Management bought 6,300 Beam Therapeutics shares in Q2 2026, an estimated $190K.
Beam Therapeutics made up 0.44% of Privium Fund Management's portfolio in Q2 2026, its #35 holding.
Privium Fund Management first reported a position in Beam Therapeutics in Q3 2025 and has held it in 4 quarters since.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.